11C-Choline Pharmacokinetics in Recurrent Prostate Cancer

被引:6
|
作者
Grkovski, Milan [1 ]
Gharzeddine, Karem [2 ]
Sawan, Peter [2 ]
Schoeder, Heiko [2 ,3 ]
Michaud, Laure [2 ]
Weber, Wolfgang A. [2 ,3 ,4 ]
Humm, John L. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med Phys, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Mol Imaging & Therapy Serv, 1275 York Ave, New York, NY 10021 USA
[4] Tech Univ Munich, Klinikum Rechts Isar, Univ Hosp, Munich, Germany
关键词
C-11-choline; dynamic PET; kinetic modeling; prostate cancer; metastasis; EMISSION-TOMOGRAPHY; BLOOD-FLOW; CHOLINE; PET; METASTASES; METABOLISM; MECHANISMS; CARCINOMA; KINETICS;
D O I
10.2967/jnumed.118.210088
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The aim of this study was to investigate the value of pharmacokinetic modeling for quantifying 11C-choline uptake in patients with recurrent prostate cancer. Methods: In total, 194 patients with clinically suspected recurrence of prostate cancer underwent 11C-choline dynamic PET over the pelvic region (0-8 min), followed by a 6-min static acquisition at about 25 min after injection. Regions of interest were drawn over sites of disease identified by a radiologist with experience in nuclear medicine. 11C-choline uptake and pharmacokinetics were evaluated by SUV, graphical analysis (Patlak plot; Ki P), and 1-and 2-compartment pharmacokinetic models (K1, K1/k2, k3, k4, and the macro parameter Ki C). Twenty-four local recurrences, 65 metastatic lymph nodes, 19 osseous metastases, and 60 inflammatory lymph nodes were included in the analysis, which was subsequently repeated for regions of interest placed over the gluteus maximus muscle and adipose tissue as a control. Results: SUVmean and Ki P were 3.60 +/- 2.16 and 0.28 +/- 0.22 min(-1) in lesions, compared with 2.11 +/- 1.33 and 0.15 +/- 0.10 min(-1) in muscle and 0.26 +/- 0.07 and 0.02 +/- 0.01 min(-1) in adipose tissue. According to the Akaike information criterion, the 2-compartment irreversible model was most appropriate in 85% of lesions and resulted in a K1 of 0.79 +/- 0.98 min(-1) (range, 0.11-7.17 min(-1)), a K1/k2 of 2.92 +/- 3.52 (range, 0.31-20.00), a k3 of 0.36 +/- 0.30 min(-1) (range, 0.00(-1).00 min(-1)) and a Ki C of 0.28 +/- 0.22 min(-1) (range, 0.00-1.33 min(-1)). The Spearman. between SUV and Ki P, between SUV and Ki C, and between Ki P and Ki C was 0.94, 0.91, and 0.97, respectively, and that between SUV and K1, between SUV and K1/k2, and between SUV and k3 was 0.70, 0.44, and 0.33, respectively. Malignant lymph nodes exhibited a higher SUV, Ki P, and Ki C than benign lymph nodes. Conclusion: Although 11C-choline pharmacokinetic modeling has potential to uncouple the contributions of different processes leading to intracellular entrapment of 11C-choline, the high correlation between SUV and both Ki P and Ki C supports the use of simpler SUV methods to evaluate changes in 11C-choline uptake and metabolism for treatment monitoring.
引用
收藏
页码:1672 / 1678
页数:7
相关论文
共 50 条
  • [21] 11C-choline PET/CT and individualization radiotherapy planning in prostate cancer
    Lopez, E.
    Lazo, A.
    Arregui, G.
    Gutierrez, A.
    Sacchetti, A.
    Nunez, M. I.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S93 - S94
  • [22] Evaluation of 11C-choline PET/CT in the diagnosis and staging of prostate cancer
    Xin, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S208 - S208
  • [23] 11C-Choline PET/CT in Prostate Cancer Patients with Biochemical Recurrence
    Pursanova, D. M.
    Aslanidis, I. P.
    Mukhortova, O. V.
    Rumyantsev, A. S.
    Karyakin, O. B.
    Biryukov, V. A.
    Shirokorad, V. I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S668 - S668
  • [24] Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography
    Castellucci, Paolo
    Ceci, Francesco
    Fanti, Stefano
    UROLOGIC CLINICS OF NORTH AMERICA, 2018, 45 (03) : 481 - +
  • [25] Dynamic 11C-Choline PET/CT for the primary diagnosis of prostate cancer
    Golan, Shay
    Nidam, Meital
    Bernstine, Hanna
    Baniel, Jack
    Groshar, David
    INTERNATIONAL BRAZ J UROL, 2018, 44 (05): : 900 - 905
  • [26] Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer
    Seitz, M
    Gratzke, C
    Schlenker, B
    Reich, O
    Stief, CG
    Scher, B
    JOURNAL OF UROLOGY, 2006, 175 (04): : 483 - 484
  • [27] 11C-Choline PET/pathology image coregistration in primary localized prostate cancer
    Anca-Ligia Grosu
    Gregor Weirich
    Christina Wendl
    Vesna Prokic
    Simon Kirste
    Hans Geinitz
    Michael Souvatzoglou
    Juergen E. Gschwend
    Markus Schwaiger
    Michael Molls
    Wolfgang A. Weber
    Uwe Treiber
    Bernd Joachim Krause
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 2242 - 2248
  • [28] Retrospective review of 11C-choline detected thoracic lesions in prostate cancer.
    Rehman, Muneeb
    Mansfield, Aaron Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [29] Dose painting in prostate cancer with simultaneous 11C-Choline PET and Multiparametric MR
    Marino, E.
    Pena, G.
    Mugneco, A.
    Aguero, H.
    Alvarez, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S430 - S431
  • [30] 11C-Choline PET/pathology image coregistration in primary localized prostate cancer
    Grosu, Anca-Ligia
    Weirich, Gregor
    Wendl, Christina
    Prokic, Vesna
    Kirste, Simon
    Geinitz, Hans
    Souvatzoglou, Michael
    Gschwend, Juergen E.
    Schwaiger, Markus
    Molls, Michael
    Weber, Wolfgang A.
    Treiber, Uwe
    Krause, Bernd Joachim
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (12) : 2242 - 2248